1. De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. Third Edition. Lippincott, Philadelphia 1989 pp 286–287
2. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987 (1):66
3. Neidhart J, Mangalik A, Kohler W, Stidley C, Saiki J, Duncan P, Souza L, Downing M: G-CSF stimulates recovery of granulocytes in patients receiving dose- intensive chemotherapy without bone marrow transplantation. J Clin Oncol 1989 (7/11):1685–1692
4. Neidhart JA, Kohler W, Stidley C, Mangalik A et al: Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation. J Clin Oncol 1990 (8/10):1728–1738
5. Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU: Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human GM-CSF. JNCI 1990 (82):667–672